Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and ARROW Trials
- Authors
- Dimopoulos, Meletios A.; Moreau, Philippe; Iida, Shinsuke; Huang, Shang-Yi; Takezako, Naoki; Chng, Wee Joo; Zahlten-Kumeli, Anita; Sersch, Martina A.; Li, Julia; Huang, Mei; Lee, Jae Hoon
- Issue Date
- Oct-2019
- Publisher
- SPRINGER JAPAN KK
- Keywords
- Carfilzomib; Relapsed and; or refractory multiple myeloma; Asian population; Clinical trials
- Citation
- INTERNATIONAL JOURNAL OF HEMATOLOGY, v.110, no.4, pp.466 - 473
- Journal Title
- INTERNATIONAL JOURNAL OF HEMATOLOGY
- Volume
- 110
- Number
- 4
- Start Page
- 466
- End Page
- 473
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/947
- DOI
- 10.1007/s12185-019-02704-z
- ISSN
- 0925-5710
- Abstract
- Carfilzomib is an irreversible proteasome inhibitor used for the treatment of relapsed and/or refractory multiple myeloma (RRMM). We evaluated the efficacy and safety of carfilzomib in subgroups of Asian patients in the randomized phase 3 ENDEAVOR and A.R.R.O.W. trials. In ENDEAVOR, patients received carfilzomib twice-weekly (56 mg/m(2)) plus dexamethasone (Kd; n = 56) or bortezomib plus dexamethasone (Vd; n = 57). In A.R.R.O.W., patients received carfilzomib once-weekly (70 mg/m(2), n = 30) or twice-weekly (27 mg/m(2), n = 15) plus dexamethasone. Median progression-free survival (PFS) among Asian patients in ENDEAVOR was longer with Kd than with Vd (14.9 versus 8.8 months; HR 0.599); the overall response rate (ORR) was 80.4% versus 70.2%. Median overall survival (Kd versus Vd) was 47.6 versus 38.8 months (HR 0.856). Median PFS among Asian patients in A.R.R.O.W. was longer for once-weekly versus twice-weekly Kd (16.0 versus 8.4 months; HR 0.628); ORR was 76.7% versus 53.3%. Rates of grade >= 3 adverse events were 89.1% (Kd) and 89.5% (Vd) in ENDEAVOR, and 76.6% (once-weekly Kd) versus 73.3% (twice-weekly Kd) in A.R.R.O.W. Overall, carfilzomib had a favorable benefit-risk profile across both dosing regimens [once-weekly (Kd 70 mg/m(2)) and twice-weekly (Kd 56 mg/m(2))] in Asian patients with RRMM, which was consistent with the results of both parent studies.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/947)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.